Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 5/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.37 |
| ▸ | WNT1 | P04628 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.35 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.35 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.35 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5482515 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2GSK3BDYRK1AWNT1ALDH1A1 | |
| SCHEMBL23896279 | 0.84 | TERT (0.40) | SMN1; SMN2TERTGSK3BALDH1A1KMT2A | |
| SCHEMBL12640328 | 0.82 | TERT (0.40) | SMN1; SMN2TERTGSK3BDYRK1AWNT1 | |
| SCHEMBL2663389 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL23291308 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2GSK3BDYRK1AWNT1ALDH1A1 | |
| SCHEMBL1965586 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2TERTGSK3BDYRK1AWNT1 | |
| SCHEMBL14971478 | 0.82 | HSD17B10 (0.44) | SMN1; SMN2TERTGSK3BDYRK1AWNT1 | |
| SCHEMBL14971479 | 0.82 | TERT (0.39) | SMN1; SMN2TERTGSK3BDYRK1AWNT1 | |
| SCHEMBL24754097 | 0.81 | SMN1; SMN2 (0.41) | SMN1; SMN2TERTGSK3BDYRK1AWNT1 | |
| SCHEMBL19011718 | 0.81 | SMN1; SMN2 (0.39) | SMN1; SMN2GSK3BDYRK1AWNT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334657-B1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-03-06 | — | — | EP | disclosed |
| EP-2334657-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| US-7858630-B2 | D3 and 5-HT2A receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858630-B2 | D3 and 5-HT2A receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7858630-B2 | D3 and 5-HT2A receptor modulators | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
| WO-2010031735-A1 | PIPERAZINE D3 AND 5-HT2A RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075983-A1 | D3 AND 5-HT2A RECEPTOR MODULATORS | HTR2A, HTR3A, HTR1A | SMN1; SMN2 3217/4885TERT 4296/4885GSK3B 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.